- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Transplantation & Cellular Therapy Meetings | Conferences
Itolizumab Induces Durable Clinical Responses in Newly Diagnosed aGVHD
February 15, 2021
For the treatment of patients with newly diagnosed acute graft-versus-host disease, itolizumab has demonstrated promise in part A of the multicenter dose-ascending phase 1b/2 EQUATE study.
Ruxolitinib Exceeds Response, Survival, and Symptom Burden End Points in Chronic GVHD
February 12, 2021
Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.
Orca-T Achieves Impressive Outcomes in Hematologic Malignancies
February 11, 2021
Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.
Safety Findings Support Use of Peri-Transplant Ruxolitinib in Myelofibrosis
February 10, 2021
Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia
February 10, 2021
Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.
Maximum Dose of Ruxolitinib Peri-transplant Is Safe and Feasible Treatment For Patients With Myelofibrosis
February 10, 2021
Data from a prospective pilot trial presented at the 2021 Transplantation and Cellular Therapy Meetings show that a maximum dose of 10 mg of ruxolitinib given peri-transplant is a safe and feasible treatment for patients with myelofibrosis.
CAR T Cells Continue May Strides in Hematologic Malignancies
February 09, 2021
Michael Bishop, MD, discusses the impact of chimeric antigen receptor T cell therapy across hematologic malignancies.
Axi-Cel Treatment Outcomes Correlate With Response to Prior Therapy in Refractory Large B-Cell Lymphoma
February 09, 2021
Treatment with axicabtagene ciloleucel is less likely to induce responses in patients with refractory large B-cell lymphoma who have never achieved a complete response to any line of prior therapy, according to findings from a single-center retrospective analysis.
Ruxolitinib Demonstrates Safety and Preliminary Efficacy in Children with cGVHD
February 09, 2021
Ruxolitinib was found to be safe for utilization in children after a pediatric dosing algorithm was tested in patients with chronic graft-versus-host disease and induced responses.
Narsoplimab Demonstrates Clinical Activity in High-Risk HSCT-TMA
February 09, 2021
In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.